Overview

Sequential TransArterial Chemoembolization and Stereotactic RadioTherapy With ImmunoTherapy for Downstaging Hepatocellular Carcinoma for Hepatectomy

Status:
Recruiting

Trial end date:
2024-02-05

Target enrollment:

Participant gender:

Summary

This study is a prospective phase II, single arm mono-institutional study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of the sequential administration of trans-arterial chemo-embolization (TACE) and stereotactic body radiotherapy (SBRT) with an immune checkpoint inhibitor in hepatocellular carcinoma (HCC) patients.

Phase:

Phase 2

Details

Lead Sponsor:

The University of Hong Kong

Collaborator:

Merck KGaA, Darmstadt, Germany

Treatments:

Immune Checkpoint Inhibitors